Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development

Author

M. Cristofanilli

h-index 10 View on Semantic Scholar

We have 4 of 37 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Circulating tumor DNA in breast cancer in 2027: advancing liquid biopsy and molecular monitoring.

PURPOSE OF REVIEW Circulating tumor DNA (ctDNA) is increasingly used for molecular profiling in breast cancer, and its role as a longitudinal biomarker is expanding. This review examines recent evidence on serial ctDNA assessment, focusing on minimal residual disease (MRD) and molecular relapse in early breast cancer (...

G. R. Oliva, M. Cristofanilli, C. Reduzzi et al. · 0 citations
Review Sep 2026

Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.

LB is progressively shifting from a research tool to a clinical decision-making instrument in HR+/HER2- mBC, and integrated multiparametric LB approaches combining CTCs and ctDNA are crucial to improve prognostic accuracy and clinical decision-making.

V. Frescura, M. Cristofanilli, C. Reduzzi et al. · 0 citations
Review Aug 2026

Inflammatory breast cancer: improving research and care through the integration of preclinical evidence and technological advances.

A comprehensive overview of current knowledge on its applications in IBC is provided, highlighting the potential of circulating biomarkers to enhance disease characterization, diagnosis, risk assessment, and personalized treatment and the promising role of artificial intelligence in improving diagnostic accuracy.

E. Nicolò, M. Manai, Amr S. Soliman et al. · 1 citation
Review Open access Jul 2026

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps

Evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance is summarized and ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.

S. Di Cosimo, V. Appierto, C. Reduzzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.